CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
6.37
-0.09 (-1.39%)
At close: Mar 18, 2026, 4:00 PM EDT
6.38
+0.01 (0.15%)
After-hours: Mar 18, 2026, 7:48 PM EDT

Company Description

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.

The company was incorporated in 2006 and is based in Parsippany, New Jersey.

CorMedix Inc.
CorMedix logo
CountryUnited States
Founded2006
IPO DateMar 25, 2010
IndustryBiotechnology
SectorHealthcare
Employees191
CEOJoseph Todisco

Contact Details

Address:
389 Interpace Pkwy, Suite 450
Parsippany, New Jersey 07054
United States
Phone908 517 9500
Websitecormedix.com

Stock Details

Ticker SymbolCRMD
ExchangeNASDAQ
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001410098
CUSIP Number21900C308
ISIN NumberUS21900C3088
SIC Code2834

Key Executives

NamePosition
Joseph Todisco MBAChief Executive Officer and Chairman of the Board of Directors
Elizabeth Masson-Hurlburt B.A.Executive Vice President, Chief Operating Officer and Chief Integration Officer
Dr. Matthew T. David M.D.Executive Vice President and Chief Business Officer
Susan BlumExecutive Vice President and Chief Financial Officer
Kaufman Beth Zelnick Esq.EVice President, Chief Legal and Compliance Officer and Corporate Secretary
Beth SteinbrennerSVice President and Chief Human Resource Officer
Donna UcciSenior Vice President and Head of Global Quality
Dr. Tushar MukherjeeSenior Vice President and Head of Technical Operations
Michael SecklerExecutive Vice President and Chief Commercial Officer
Dr. Peter Sullivan BCOP, Pharm.D.Senior Vice President of Market Access

Latest SEC Filings

DateTypeTitle
Mar 6, 20268-KCurrent Report
Mar 5, 202610-KAnnual Report
Mar 5, 20268-KCurrent Report
Jan 21, 2026144Filing
Jan 8, 20268-KCurrent Report
Jan 2, 2026SCHEDULE 13G/AFiling
Dec 30, 2025144Filing
Dec 18, 2025144Filing
Dec 9, 2025144Filing
Dec 9, 2025144Filing